Drug Trial Radar · NCT00316264
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
Last checked: Nov 20, 2026Latest source record: Dec 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Apr 2006
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and palivizumab were administered sequentially to high-risk children during the same respiratory syncytial virus (RSV) season. A control group was administered only motavizumab.
Conditions
- Respiratory Syncytial Virus Infections
- Chronic Lung Disease and <= 24 Months of Age or
- Premature With Gestational Age <=35 Weeks and <=6 Months of Age
Interventions
Motavizumab, palivizumabBiological
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Palivizumab, motavizumabBiological
Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
MotavizumabBiological
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Serious Adverse Events (SAEs)Time frame: Day 0 - Day 150
- Number of Subjects Reporting Adverse Events (AEs)Time frame: Day 0 - Day 150
- Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.Time frame: Day 0 - Day 150
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
Department of Paediatrics and Child Health, The Canberra Hospital
Garran, Australian Capital Territory, Australia
Neonatalogy John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Caboolture Clinical Research
Caboolture, Queensland, Australia
University of Queensland, Royal Children's Hospital
Herston, Queensland, Australia
Peninsula Clinical Research Centre
Kippa-Ring, Queensland, Australia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
Respiratory Medicine Department, Royal Children's Hospital
Parkville, Victoria, Australia
Hospital Clinico de la Pontificia Universidad Catolica de Chile
Santiago, Chile
Hospital Clinico San Borja Arriaran
Santiago, Chile
Hospital Dr Felix Bulnes Cerda
Santiago, Chile
Hospital Dr. Sotero del Rio
Santiago, Chile
Hospital Padre Hurtado
Santiago, Chile
Hospital Clinico de la Universidad de Chile
Independencia, Santiago Metropolitan, Chile
Hospital San Jose
Independencia, Santiago Metropolitan, Chile
Christchurch Women's Hospital
Christchurch, New Zealand
Paediatric Medicine, Dunedin Hospital
Dunedin, New Zealand
Department of Paediatrics, Waikato Hospital
Hamilton, New Zealand
Child Health, Palmerston North Hospital
Palmerston North, New Zealand
Kidz First, Middlemore Hospital
Otahuhu, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.